Introduction
============

Lung cancer is the leading cause of cancer-related deaths worldwide, and is the primary cause of cancer deaths in men and the secondary cause in women[@B1]. Non-small cell lung cancer (NSCLC) is found in 80% of patients with lung cancer and 75% of patients are diagnosed at an advanced stage with a poor prognosis. Most patients with advanced NSCLC progress despite therapeutic intervention due to limited treatment success[@B2],[@B3],[@B4]. Platinum-based chemotherapy remains the standard treatment for NSCLC patients; however, epidemiologic studies suggest that its contribution has reached a therapeutic plateau[@B5]. Thus, new treatment strategies are required. Neovascularization of lung cancer plays an important role in cancer cell growth and metastasis[@B6]. Several vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs) have shown clinical benefits when added to standard chemotherapy. During tumor development, the angiogenic switch is associated with the onset of expression and secretion of angiogenic factors by tumor cells. Neovasculature is crucial for the growth and survival of tumors larger than 3 mm^3^ in volume as it ensures the supply of oxygen and nutrients to cancer cells. In addition, it promotes metastasis by facilitating the entrance of tumor cells into the circulation system by fragile newly formed vessels[@B7]. VEGFR-TKIs inhibit the sprouting of vessels by blocking those activating signal pathways. Unlike classic cytotoxic drugs, VEGFR-TKIs have no direct cell-killing effect on lung cancer cells. It was shown in vitro that anti-VEGFR therapy contributes to normalization of tumor neovascular and enhances antitumor activity. VEGFR-TKIs in combination with chemotherapy results in cancer cell death and rapid tumor shrinkage[@B8]. However, whether VEGFR-TKIs in combination with chemotherapy can prolong survival and lower the number of adverse effects (AEs) requires further evaluation.

The use of VEGFR-TKIs in combination with chemotherapy as first-line or more than second-line agents for the treatment of patients with NSCLC has been evaluated, but the results on the efficacy and safety of such therapies are inconsistent. Nintedanib in combination with docetaxel is an effective second-line treatment for advanced lung adenocarcinoma in patients previously treated with first-line platinum-based therapy[@B9],[@B10],[@B11]. Axitinib showed promising single agent activity with an acceptable safety profile in an open label, single arm, phase II trial in advanced NSCLC[@B12]. Vandetanib, pazopanib, cediranib, and linifanib have also demonstrated higher efficiency when combined with chemotherapy in NSCLC[@B13],[@B14],[@B15]. However, some negative results have been observed following treatment with VEGFR-TKIs in combination with chemotherapy for advanced NSCLC patients. Motesanib combined with carboplatin-paclitaxel in non-squamous NSCLC, failed to provide an OS benefit, while demonstrating higher grade toxicity[@B16]. Sunitinib is a small oral TKI that targets VEGFR-1/2/3. In a controlled study, data analysis showed no benefit following treatment with sunitinib in unselected or non-squamous NSCLC patients[@B17]. Many clinical trials have demonstrated that VEGFR-TKIs with chemotherapy can improve survival outcomes in NSCLC patients. However, to date, nintedanib is the only VEGFR-TKI permitted by the USA and Europe for the treatment of advanced NSCLC. Many studies have reported no clinical benefits of VEGFR-TKIs when used in combination with chemotherapy[@B18],[@B19].

A previous meta-analysis showed that therapy consisting of chemotherapy plus VEGFR-TKIs has specific advantages over chemotherapy alone in terms of progression-free survival (PFS) and objective response rate (ORR), but the combination therapy did not prolong overall survival (OS) and disease control rate (DCR)[@B20]. Thus, we performed an updated meta-analysis to summarize the efficacy and safety of VEGFR-TKIs in combination with chemotherapy for patients with advanced NSCLC.

Methods
=======

Literature search
-----------------

We searched PubMed, PMC database, EMBASE, EBSCO-Medline, Cochrane Central Register of Controlled Trials (CENTRAL), American Society of Clinical Oncology (ASCO), International Association for the Study of Lung Cancer (IASLC) and the European Society of Medical Oncology (ESMO), <http://www.clinicaltrials.gov/>, CNKI, Wanfang, and VIP databases using common keywords related to VEGFR-TKIs and NSCLC. The following keywords were included: *VEGFR-TKI or vascular endothelial growth factor receptor tyrosine kinase inhibitors, lung cancer or NSCLC*. We reviewed the bibliographies of relevant articles for additional publications.

Selection criteria
------------------

We included trials that met the following criteria: (i) the trial enrolled patients with cytologically or pathologically confirmed advanced NSCLC (males or females aged at least 18 years); (ii) the trial design was a randomized controlled trial (RCT) comparing VEGFR-TKIs in combination with chemotherapy with chemotherapy alone; (iii) the trial reported survival related outcomes, such as OS, PFS, ORR and DCR; (iv) the trial evaluated the safety of VEGFR-TKIs and reported AEs, such as hypertension, rash, nausea, vomiting, diarrhea, and neutropenia.

Data extraction and quality evaluation
--------------------------------------

Two independent investigators reviewed all the articles independently and discussed the articles until a consensus was reached. Data obtained from the studies included the first author, year of publication, patient source (region), type of study, number of patients, therapeutic regimen, survival outcomes, and safety data. The scale of risk of bias summary and risk of bias graph were used to assess the methodological quality of the included studies.

Statistical analysis
--------------------

We chose OS and PFS as the endpoints in our meta-analysis. ORR and DCR are also summarized in Table [1](#T1){ref-type="table"}. Safety outcomes were evaluated using STATA 14.0 (Stata Corp., College Station, TX, USA). HR was used as a measure of the prognostic value. Subgroup analyses were performed based on variables such as line of treatment.

Publication bias was evaluated according to the funnel plot and Begg\'s and Egger\'s tests using Review Manager 5.3.5. Heterogeneity was assessed by the χ^2^ test and expressed by the *I*[@B2] index.

Results
=======

Characteristics of the included studies and risk of bias
--------------------------------------------------------

In total, 20 eligible studies with information on 8,366 patients were included in this meta-analysis. A flow chart of retrieval and selection of the studies is shown in Fig. [1](#F1){ref-type="fig"}. Table [1](#T1){ref-type="table"} summarizes the basic characteristics of the included studies. All 20 studies were double-blinded and allocation concealment was adequate in all studies. The risk of bias items for each included study are presented in Fig. [2](#F2){ref-type="fig"}.

Meta-analysis of survival outcome
---------------------------------

### Progression-free survival

We identified 16 eligible trials[@B11],[@B16],[@B17],[@B18],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32], which included 8,092 patients, and investigated PFS following VEGFR-TKIs in combination with chemotherapy versus chemotherapy alone. Our meta-analysis revealed that VEGFR-TKIs in combination with chemotherapy increased PFS compared with chemotherapy alone (HR, 0.82; 95% CI, 0.78-0.87; *P* \< 0.00001, Fig. [3](#F3){ref-type="fig"}A). In the subgroup analyses, both first-line treatment (HR, 0.83; 95% CI, 0.77-0.89; *P* \< 0.00001, Fig. [4](#F4){ref-type="fig"}A) and more than second-line treatment (HR, 0.82; 95% CI, 0.76-0.88; *P* \< 0.00001, Fig. [4](#F4){ref-type="fig"}B) prolonged PFS.

### Overall survival

We identified 15 eligible trials[@B11],[@B16],[@B17],[@B18],[@B21],[@B22],[@B23],[@B24],[@B25],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32], which included 7,379 patients, and investigated OS following VEGFR-TKIs in combination with chemotherapy versus chemotherapy alone. Our meta-analysis revealed that VEGFR-TKIs in combination with chemotherapy had no impact on OS compared with chemotherapy (HR, 0.94; 95% CI, 0.89-1.00;*P* = 0.05, Fig. [3](#F3){ref-type="fig"}B). In the subgroup analyses, neither first-line treatment (HR, 0.94; 95% CI, 0.86-1.02;*P* = 0.13, Fig. [4](#F4){ref-type="fig"}C) nor more than second-line treatment (HR, 0.94; 95% CI, 0.86-1.03; *P* = 0.19, Fig. [4](#F4){ref-type="fig"}D) prolonged OS.

### Overall response rate and disease control rate

Thirteen trials reported the ORR [@B16],[@B21],[@B22],[@B25],[@B27],[@B28],[@B30],[@B32],[@B33],[@B34],[@B35],[@B36],[@B37],[@B38], and ten studies reported the DCR [@B22],[@B25],[@B27],[@B31],[@B32],[@B33],[@B34],[@B35],[@B36],[@B37]. Our meta-analysis revealed that VEGFR-TKIs in combination with chemotherapy prolonged ORR and DCR (HR, 1.72; 95% CI, 1.34-2.22; *P* \< 0.0001, Fig. [3](#F3){ref-type="fig"}C; HR, 1.45; 95% CI, 1.26-1.67; *P* \< 0.00001, Fig. [3](#F3){ref-type="fig"}D, respectively). In the subgroup analyses, both first-line treatment (HR, 1.45; 95% CI, 1.29-1.64; *P* \< 0.00001, Fig. [4](#F4){ref-type="fig"}E) and second-line treatment (HR, 1.60; 95% CI, 1.31-1.94; *P* \< 0.00001, Fig. [4](#F4){ref-type="fig"}F) prolonged the ORR. In addition, only second-line treatment (HR, 1.29; 95% CI, 1.00-1.26; *P* \< 0.00001, Fig. [4](#F4){ref-type="fig"}H) rather than first-line treatment (HR, 1.04; 95% CI, 0.93-1.17; *P* = 0.47, Fig. [4](#F4){ref-type="fig"}G) improved the DCR.

Safety outcomes
---------------

The safety results related to the use of VEGFR-TKIs in combination with chemotherapy for NSCLC patients in all 20 studies are shown in Fig. [5](#F5){ref-type="fig"}. Patients treated with VEGFR-TKIs in combination with chemotherapy were found to have more high grade (≥ 3) AEs. Hemorrhage (RR, 8.32; 95% CI, 3.84-18.04; *P* = 0.000), hypertension (RR, 4.77; 95% CI, 2.85-7.97; *P* = 0.000), neutropenia (RR, 1.26; 95% CI, 1.11-1.44; *P* = 0.000), rash (RR, 6.31; 95% CI, 4.05-9.84; *P* = 0.000), vomiting (RR, 1.26; 95% CI, 1.11-1.44; *P* = 0.000), and diarrhea (RR, 2.52; 95% CI, 1.88-3.39; *P* = 0.000) were significantly increased in NSCLC patients treated with VEGFR-TKIs in combination with chemotherapy. The risk of anemia, nausea, and constipation were comparable between the two groups (RR, 0.80; 95% CI, 0.60-1.07; RR, 1.04; 95% CI, 0.67-1.62; RR, 1.18; 95% CI, 0.40-3.50, respectively). The RRs of all high grade (≥ 3) AEs are summarized in Fig. [5](#F5){ref-type="fig"}.

Publication bias
----------------

There was no evidence of publication bias following assessment by funnel plot, Egger\'s test (*P* \> 0.05) and Begg\'s test (*P* \> 0.05).

Discussion
==========

Current treatment options for patients with advanced NSCLC are limited. Survival results and safety and tolerability findings are inconsistent in studies of various VEGFR-TKIs; thus, a statistical meta-analysis of these articles is needed. A particular focus in the treatment of NSCLC patients is survival outcome. Our results demonstrated that VEGFR-TKIs in combination with chemotherapy prolonged the PFS, ORR, and DCR, but had no impact on the OS. VEGFR-TKIs in combination with chemotherapy increased the incidence of some high grade (≥ 3) AEs, such as hemorrhage, hypertension, neutropenia, rash, vomiting, and diarrhea. With regard to the line of treatment, the efficacy of VEGFR-TKIs in combination with chemotherapy may be different in the first-line and second-line settings. Significant PFS and ORR benefits were observed in both the first-line and second-line settings. DCR benefits were observed only in second-line treatment. However, there were no OS benefits either in the first-line or the second-line setting. A previous meta-analysis also showed no OS survival benefit[@B20]. It seems that although the VEGFR-TKIs have been proven to be effective in terms of the PFS, it was limited due to modest OS because of resistance during treatment. However, fibroblast growth factor (FGF) and platelet-derived growth factor (PDGF) have been found to be upregulated in patients exhibiting acquired resistance to anti-VEGF treatment and that the combination of VEGF/PDGF pathways has been proven to be more effective than single VEGF inhibition in animal models. The use of multi-targeted anti-angiogenesis TKIs in combination with chemotherapy seems to be a promising strategy for advanced NSCLC patients[@B39],[@B40],[@B41].

Several multi-targeted anti-angiogenesis TKIs, such as sorafenib, axitinib, cediranib, nintedanib, pazopanib, linifanib, motesanib are under clinical investigation and have not been approved for the treatment of patients with advanced NSCLC. The ZODIAC study demonstrated significant prolongation of PFS with vandetanib plus docetaxel versus docetaxel alone. This study showed that adding vandetanib significantly improved the ORR and delayed the time to worsening of lung cancer symptoms[@B28]. In the second-line setting of NSCLC, it was previously shown that the doublet combination of single cytotoxic agents and vandetanib, was safe and demonstrated antitumor activity[@B11],[@B42]. Nintedanib improved the OS in a population of adenocarcinoma patients, particularly those with progression within 9 months after first-line treatment initiation[@B26]. In a phase II trial, first-line linifanib in combination with carboplatin-paclitaxel was associated with a higher ORR, PFS, and OS[@B31]. However, some clinical trials have reported negative results for VEGFR-TKIs in advanced NSCLC. Axitinib is a second-generation oral TKI of VEGF receptor 1, 2 and 3, PDGFR-b and c-kit, and has shown activity against several tumors. A phase II study evaluating the combination of axitinib with chemotherapy in non-squamous NSCLC not only failed to demonstrate a survival benefit, but also reported higher grade 3-4 toxicity[@B21]. Sorafenib, ceritinib, pazopanib, and motesanib also did not lead to a PFS or OS benefit in first-line treatment compared with chemotherapy alone[@B9],[@B16],[@B18],[@B22],[@B25],[@B29]. Among the Chinese patients in phase II and phase III clinical trial, anlotinib appears to lead to prolonged overall survival and progression-free survival. Those findings suggest that anlotinib is well tolerated and is a potential third-line or further therapy for patients with advanced NSCLC[@B37],[@B38],[@B43]. However, our object was to evaluate VEGFR-TKIs and chemotherapy in comparison with chemotherapy. Thus, studies of anlotinib don\'t meet our inclusion criteria and are not included in our meta-analysis.

In our meta-analysis, VEGFR-TKIs in combination with chemotherapy improved the PFS, ORR and DCR in patients with advanced NSCLC, indicating that slowing disease progression also slowed symptom progression, leading to an important palliative benefit. This improvement in PFS, ORR, and DCR raises the possibility that patients with advanced NSCLC can live with fewer symptoms for a longer periods of time. However, there was no significant effect on the OS. EGFR expression, overexpression, and mutation have been implicated in the pathogenesis of NSCLC, suggesting that EGFR positive patients may derive increased clinical benefit from EGFR-targeted treatments. Thus, absence of the selection of EGFR positive patients may be a possible explanation for the negative results obtained for OS in patients treated with VEGFR-TKIs in combination with erlotinib. An accurate understanding of the expression levels and localization of drug targets in NSCLC is necessary to elucidate the mechanism of action of drugs in the clinic and, potentially, for identifying patients who would gain most clinical benefit from VEGFR-TKIs treatment. In addition, many patients received post-progression therapy, and although the number of patients and type of therapy received were balanced between groups before progression, the possibility that differences in response to post-progression therapy cannot be excluded.

Another focus of the treatment of NSCLC patients is safety and tolerability. VEGFR-TKIs in combination with chemotherapy resulted in more high grade (≥ 3) AEs than chemotherapy alone, such as rash, hemorrhage, neutropenia, hypertension, and diarrhea. Hypertension is a well-known AE of VEGFR-TKIs. It is known that VEGFR-TKIs induce vasoconstriction by inhibiting flow-mediated dilation[@B47]. Interestingly, the occurrence of treatment-related hypertension is associated with the benefit of VEGFR-TKIs[@B48]. The VEGF signal pathway plays an important role in hematopoiesis. Therefore, VEGFR-TKIs may lead to neutropenia. Furthermore, the increased overall incidence of AEs probably reflects the additive effects of the drug combination, for example, the addition of vandetanib to docetaxel resulted in higher rates of grade 3-4 diarrhea, neutropenia, and rash [@B28]. In addition, another reason for these AEs may be the antiangiogenic effects in normal tissues that could destroy the network of capillaries in healthy lung tissues. VEGFR-TKIs change tumor vessel physiology, resulting in increased intratumoral uptake of drugs[@B49]. The body grows new blood vessels during wound healing, and as collateral circulation around blocked or atherosclerotic blood vessels. One concern is that VEGFR-TKIs may interfere with these normal processes, and worsen conditions such as coronary artery disease or peripheral artery disease. The risk of anemia, nausea, and constipation were comparable between the two groups. One possible explanation for this is the potential benefit of VEGFR-TKIs in reducing tumor growth. Another explanation might be the increase in erythropoietin induced by the antiangiogenic effect[@B50]. However, the mechanism has not been fully evaluated and further studies are required. In addition, the lower rate of treatment-related toxic effects indicated that the treatment was tolerable and manageable.

Our study has important limitations. Despite the RCT design, there were slight imbalances in sex and prior lines of therapy in the included trials. Differences between groups in the use of and response to post-progression therapies may confound the DCR and OS outcome. The outcome estimates were taken from published data; thus, systematic biases could not be minimized and the data in some cases were incomplete. Thus, further research should focus on high quality studies and clinical features in patients with comprehensive evaluation to obtain a more standardized study design and more accurate conclusions.

Clearly, there is an urgent need for a better understanding of the complex nature of tumor angiogenesis and how VEGFR-TKIs affect tumor vasculature and cellular components within the tumor microenvironment[@B51].

Conclusions
===========

The results of this meta-analysis showed that VEGFR-TKIs in combination with chemotherapy prolonged the PFS, ORR, and DCR in patients with advanced NSCLC, but had no impact on the OS.
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###### 

Eligible clinical studies for clinical meta-analysis and their characteristics

  Author                               Agents       Year                                           Country                                        Line of treatment   Phase            Regimens                                    Number of patients   Median OS (months)   Median PFS (months)   ORR    DCR
  ------------------------------------ ------------ ---------------------------------------------- ---------------------------------------------- ------------------- ---------------- ------------------------------------------- -------------------- -------------------- --------------------- ------ ------
  Luis Paz-Ares                        Sorafenib    2012                                           Spain                                          First               III              Sorafenib + gemcitabine + cisplatin vs.     385                  12.4                 6                     27.8   62.1
  placebo                              387          12.5                                           5.5                                            25.8                63.1                                                                                                                                
                                                    (HR 0.98, *P =* 0.401)                         (HR 0.83, *P =* 0.008)                         (*P* = 0.11)        (*P* = 0.47)                                                                                                                        
  Giorgio Scagliotti                   Sorafenib    2010                                           Italy                                          First               III              Sorafenib + paclitaxel + carboplatin vs.    464                  10.7                 4.6                          
  placebo + paclitaxel + carboplatin   462          10.6                                           5.4                                                                                                                                                                                                    
                                                    (HR 1.15, 95% CI 0.94-1.41, *P* = 0.915)       (HR 0.99, 95% CI 0.84-1.16, *P* = 0.433)                                                                                                                                                               
  Yan Wang                             Sorafenib    2011                                           China                                          First               NR               Sorafenib + gemcitabine + cisplatin vs.     18                   18                   5                     55.6   88.9
  placebo + gemcitabine + cisplatin    12           18                                             4                                              41.7                100                                                                                                                                 
                                                    (*P* = 0.68)                                   (*P* = 0.750)                                  (*P* = 0.905)                                                                                                                                           
  Lihong Zhang                         Sorafenib    2014                                           China                                          First               NR               Sorafenib + gemcitabine + cisplatin vs.     12                   12.8                 7.4                   33.3   75
  placebo + gemcitabine + cisplatin    17           12.7                                           4.3                                            11.8                88.2                                                                                                                                
                                                    (*P* = 0.369)                                  (*P* = 0.070)                                  (*P* = 0.172)       (*P* = 0.234)                                                                                                                       
  John V. Heymach                      Vandetanib   2008                                           Spain                                          First               II               Vandetanib + paclitaxel + carboplatin vs.   56                                        6                            
  placebo + paclitaxel + carboplatin   52                                                          5.75                                                                                                                                                                                                   
                                                    (HR 1.15, 95% CI, 0.75-1.77)                   (HR 0.76, 95% CI, 0.51-1.14)                                                                                                                                                                           
  John V. Heymach                      Vandetanib   2007                                           Spain                                          Second              II               Vandetanib + docetaxel vs.                  42                   13.1                 4.7                          
  placebo + docetaxel                  41           13.4                                           3                                                                                                                                                                                                      
                                                    (HR 0.91, 95% CI, 0.55-1.52, P = 0.0361)       (HR 0.64, 95% CI, 0.38-1.05, P = 0.037)                                                                                                                                                                
  Prof Roy Herbst                      Vandetanib   2011                                           USA                                            Second              III              Vandetanib + docetaxel vs.                  694                  10.3                 4                     17     
  docetaxel                            697          9.9                                            3.2                                            10                                                                                                                                                      
                                                    (HR 0.91, 97.52% CI 0.78-1.07, *P* \<0·0001)   (HR 0.79, 97.58% CI 0.70-0.90, *P* \<0·0001)   (*P* = 0·0001)                                                                                                                                          
  Richard H. de Boer                   Vandetanib   2011                                           Australia                                      Second              III              Vandetanib + pemetrexed vs.                 256                  10.5                 4.1                   19     57
  placebo + pemetrexed                 278          9.2                                            2.8                                            8                   46                                                                                                                                  
                                                    (HR 0.86, 97.54% CI 0.65-1.13, *P* = 0.219)    (HR 0.86, 97.58% CI 0.69-1.06, *P* = 0.108)    (*P* \< 0.001)      (*P* = 0.0116)                                                                                                                      
  Gridelli                             Vandetanib   2014                                           Italy                                          First               II               Vandetanib + gemcitabine vs.                61                   8.7                  6.1                   15     72
  placebo + gemcitabine                63           10.2                                           5.6                                            13                  67                                                                                                                                  
                                                                                                                                                                                                                                                                                                          
  Martin Reck                          Nintedanib   2014                                           Germany                                        Second              III              Nintedanib + docetaxel vs.                  655                  10.1                 3.4                   35.1   73.6
  placebo + docetaxel                  659          9.1                                            2.7                                            30.1                68.3                                                                                                                                
                                                    (HR 0.94, 95% CI 0.83-1.05, *P* = 0.2720)      (HR 0.79, 95% CI 0.68-0.92, *P* = 0.0019)                                                                                                                                                              
  Hanna                                Nintedanib   2013                                           Germany                                        Second              III              Nintedanib + pemetrexed vs.                 353                                       4.4                   9      61
  placebo + pemetrexed                 360                                                         3.6                                            9                   53                                                                                                                                  
                                                                                                   (HR 0.83, 95% CI 0.70-0.99)                                                                                                                                                                            
  Chandra P Belani                     Axitinib     2014                                           USA                                            First               II               Axitinib + PEM + DDP vs.                    55                   17                   8                     45.5   
  PEM + DDP                            57           15.9                                           7.1                                            26.3                                                                                                                                                    
                                                    (HR 1.05, 95% CI, 0.65-1.69, P = 0.58)         (HR 0.89, 95% CI, 0.56-1.42, P = 0.036)                                                                                                                                                                
  Giorgio Scagliotti                   pazopanib    2013                                           Italy                                          First               II               pazopanib+ PEM + DDP vs.                    62                                                              14     27
  PEM + DDP                            35                                                                                                         12                  26                                                                                                                                  
                                                    (HR 1.22, 95% CI, 0.64-2.33, P = 0.5519)       (HR 0.75, 95% CI, 0.43-1.28, P = 0.2647)                                                                                                                                                               
  S.A. Laurie                          cediranib    2014                                           Canada                                         First               III              cediranib + carboplatin + paclitaxel vs.    151                  12.2                 5.5                          
  carboplatin + paclitaxel             153          12.1                                           5.5                                                                                                                                                                                                    
                                                    (HR 0.94, 95% CI, 0.69-1.30, P = 0.72)         (HR 0.91, 95% CI, 0.71-1.18, P = 0.49)                                                                                                                                                                 
  Glenwood D. Goss                     cediranib    2010                                           Canada                                         First               II/III           Cediranib + carboplatin + paclitaxel vs.    126                  10.5                 5.6                          
  carboplatin + paclitaxel             125          10.1                                           5                                                                                                                                                                                                      
                                                    (HR 0.78, 95% CI, 0.57-1.06, *P* = 0.11)       (HR 0.77, 95% CI, 0.56-1.08, *P* = 0.13)                                                                                                                                                               
  Grace K. Dy                          cediranib    2013                                           USA                                            First               II               Cediranib + carboplatin + gemcitabine vs.   58                   12                   6.3                   19     
  carboplatin + gemcitabine            29           9.9                                            4.5                                            20                                                                                                                                                      
                                                    (HR 0.66, 95% CI, 0.41-1.08)                   (HR 0.69, 95% CI, 0.43-1.09)                                                                                                                                                                           
  Ramalingam                           Linifanib    2015                                           USA                                            First               II               Linifanib + carboplatin + paclitaxel vs.    44                   11.4                 8.3                          43
  placebo + carboplatin + paclitaxel   47           11.3                                           5.4                                                                26                                                                                                                                  
                                                    (HR 1.08)                                      (HR 0.51)                                                                                                                                                                                              
  Heist                                Sunitinib    2014                                           USA                                            Second              II               Sunitinib + pemetrexed vs.                  41                   6.7                  3.7                          
  pemetrexed                           42           10.5                                           4.9                                                                                                                                                                                                    
                                                    (HR 2.0, 95% CI, 1.2-3.2)                      (HR 1.3, 95% CI, 0.9-2.1)                                                                                                                                                                              
  Scagliotti                           Motesanib    2012                                           Italy                                          First               III              Motesanib + carboplatin + paclitaxel vs.    541                  13.5                 5.6                   39     
  placebo + carboplatin + paclitaxel   549          11                                             5.4                                            25                                                                                                                                                      
                                                    (HR 0.88, 95% CI, 0.75-1.03)                   (HR 0.78, 95% CI, 0.67-0.91)                                                                                                                                                                           
  Kubota                               Motesanib    2014                                           Japan                                          First               III              Motesanib + carboplatin + paclitaxel vs.    110                  20.9                 7                     62     91
  placebo + carboplatin + paclitaxel   117          14.5                                           5.3                                            27                  77                                                                                                                                  
                                                    (HR 0.669, 95% CI, 0.473-0.946)                (HR 0.58, 95% CI, 0.42-0.79)                                                                                                                                                                           

Abbrevations: OS, overall survival; PFS, progression-free survival; ORR, objective response rate; DCR, disease control rate.
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